1. Home
  2. CTMX vs CNDT Comparison

CTMX vs CNDT Comparison

Compare CTMX & CNDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • CNDT
  • Stock Information
  • Founded
  • CTMX 2008
  • CNDT 2016
  • Country
  • CTMX United States
  • CNDT United States
  • Employees
  • CTMX N/A
  • CNDT N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • CNDT Business Services
  • Sector
  • CTMX Health Care
  • CNDT Consumer Discretionary
  • Exchange
  • CTMX Nasdaq
  • CNDT Nasdaq
  • Market Cap
  • CTMX 380.9M
  • CNDT 393.4M
  • IPO Year
  • CTMX 2015
  • CNDT N/A
  • Fundamental
  • Price
  • CTMX $1.91
  • CNDT $2.43
  • Analyst Decision
  • CTMX Strong Buy
  • CNDT
  • Analyst Count
  • CTMX 3
  • CNDT 0
  • Target Price
  • CTMX $5.67
  • CNDT N/A
  • AVG Volume (30 Days)
  • CTMX 3.1M
  • CNDT 1.0M
  • Earning Date
  • CTMX 08-07-2025
  • CNDT 08-06-2025
  • Dividend Yield
  • CTMX N/A
  • CNDT N/A
  • EPS Growth
  • CTMX 263.20
  • CNDT N/A
  • EPS
  • CTMX 0.49
  • CNDT 0.06
  • Revenue
  • CTMX $141,100,000.00
  • CNDT $3,112,000,000.00
  • Revenue This Year
  • CTMX N/A
  • CNDT N/A
  • Revenue Next Year
  • CTMX N/A
  • CNDT $2.85
  • P/E Ratio
  • CTMX $3.91
  • CNDT $39.53
  • Revenue Growth
  • CTMX 18.01
  • CNDT N/A
  • 52 Week Low
  • CTMX $0.40
  • CNDT $1.90
  • 52 Week High
  • CTMX $3.10
  • CNDT $4.90
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 39.81
  • CNDT 39.55
  • Support Level
  • CTMX $1.72
  • CNDT $2.43
  • Resistance Level
  • CTMX $2.43
  • CNDT $2.67
  • Average True Range (ATR)
  • CTMX 0.20
  • CNDT 0.13
  • MACD
  • CTMX -0.06
  • CNDT -0.01
  • Stochastic Oscillator
  • CTMX 26.84
  • CNDT 19.15

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About CNDT Conduent Incorporated

Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.

Share on Social Networks: